AstraZeneca, Johnson & Johnson COVID-19 vaccine trials to resume

Johnson & & Johnson is likewise set to resume its trial, about 2 weeks after pausing it due to a participants unexplained health problem. Two confidential sources told The Washington Post security private investigators identified the participants stroke did not appear to be connected to the vaccine.

AstraZeneca put global trials for its COVID-19 vaccine candidate on hold after discovering that a U.K. trial participant had developed a case of transverse myelitis. The drugmaker resumed the trial in the U.K. Sept. 12 after gaining approval from the Medicines Health Regulatory Authority, the countrys equivalent of the FDA. AstraZeneca got FDA clearance to continue its U.S. trial Oct. 23.

The COVID-19 vaccine trials for AstraZeneca and Johnson & & Johnson– which were willingly paused on Sept. 9 and Oct. 12, respectively– are resuming after independent review panels verified their security.

More short articles on pharmacy: AstraZeneca COVID-19 vaccine trial delays: A timelineRemdesivir ends up being first FDA-approved COVID-19 treatmentA breakdown of the 4 COVID-19 vaccine trials in late-stage testing.

” The reboot of clinical trials across the world is excellent news, as it allows us to continue our efforts to develop this vaccine to assist defeat this horrible pandemic,” AstraZeneca CEO Pascal Soriot said in a press release. “We should be assured by the care taken by independent regulators to protect the general public and ensure the vaccine is safe prior to it is approved for usage.”.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.

Katie Adams –
Monday, October 26th, 2020
Print|Email.

” With the details which we gathered to date and the information from external specialists, the business discovered no proof the vaccine prospect triggered it,” Paul Stoffels, Johnson & & Johnsons primary scientific officer, informed The Washington Post.

AstraZeneca put worldwide trials for its COVID-19 vaccine candidate on hold after learning that a U.K. trial participant had developed a case of transverse myelitis. The drugmaker resumed the trial in the U.K. Sept. 12 after gaining approval from the Medicines Health Regulatory Authority, the countrys equivalent of the FDA. AstraZeneca got FDA clearance to continue its U.S. trial Oct. 23.